FOR IMMEDIATE RELEASE: AUG 27, 2021
Boston, MA: Koning has been selected as a finalist to present at the Women’s Health Innovation Summit on September 14, 2021. Of over 100 applicants, Koning is one of only ten companies that has been chosen and will showcase the Koning Breast CT – a technology that will change millions of women’s lives around the world through no compression, low dose, and true 3D imaging.
“It’s an honor to be selected to present at this conference. I’m looking forward to speaking about the progress we’re making in bringing the breast imaging industry into the future. There’s a lot to be said about how our Koning Breast CT will positively impact women across the globe,” says Koning’s US CEO, Lutao Ning, who will be presenting at the summit.
About the Women’s Health Innovation Summit and Finalist Selection
The summit is the sector’s leading platform committed to strengthening the network, tackling unmet needs and championing innovative approaches and solutions. The focus is not only on female-only health challenges, but female-prevalent diseases and those conditions that affect or present differently in women.
Ten finalists have been chosen by the WHIS Selection Committee, and will present their company on both the Boston and virtual stage at the summit in a quick-fire round of presentations. The companies will all bring unique perspectives on the future of Women’s Health, and will speak about what their role is in that journey.
Koning will be joined by a wide range of companies across the women’s health sector, including but not limited to Atlantic Therapeutics, GSK, Frost & Sullivan, Bayer, and more, as well as investors that focus on the women’s healthcare industry.
For more information about the summit and to download the agenda, please visit the Women’s Health Innovation Summit website.
About Koning: Koning is a global HealthTech company that focuses on improving the breast imaging industry with its patented Koning Breast CT (KBCT). Koning’s vision is to create a revolution in medical imaging through advanced computed tomography technology and dramatically improve the way clinicians visualize and evaluate breast tissue. The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. Visit our repulic.co campaign to find out about how you can support Koning’s vision.